MIRM
Mirum Pharmaceuticals, Inc.
MIRM has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over MIRM overall, supported by stronger fundamentals and stronger modeled upside.
MIRM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Weak |
MIRM's revenue is currently healthy, but its profitability, cash flow and balance sheet are weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MIRM PE Valuation
MIRM has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MIRM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect MIRM's losses to grow, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over MIRM on the outlook, with more favorable earnings and profitability expectations.
MIRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$15.46 | -$14.60 |
| Q2 2026 | -$14.54 | -$13.33 |
| Q1 2026 | -$13.60 | -$11.99 |
| Q4 2025 | -$0.47 | +$1.38 |
| Q3 2025 | -$0.86 | +$1.19 |
| Q2 2025 | -$1.21 | +$1.11 |
| Q1 2025 | -$1.61 | +$2.13 |
| Q4 2024 | -$1.85 | +$2.15 |
MIRM lost $15.46 per share over the past year, and its loss has widened in each of the last three quarters.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MIRM on earnings quality, reporting a profit while its opponent remains loss making.
MIRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $185.7M | +40% |
| Q2 2026 | $176.2M | +38% |
| Q1 2026 | $159.9M | +43% |
| Q4 2025 | $148.9M | +50% |
| Q3 2025 | $133M | +47% |
| Q2 2025 | $127.8M | +64% |
| Q1 2025 | $111.6M | +61% |
| Q4 2024 | $99.4M | +43% |
MIRM's revenue has grown year over year every quarter since mid-2022: $186M last quarter, up 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -32% | -34 points |
| Q2 2026 | -24% | -20 points |
| Q1 2026 | -494% | -480 points |
| Q4 2025 | -3.1% | +21 points |
| Q3 2025 | 2% | +16 points |
| Q2 2025 | -3.9% | +27 points |
| Q1 2025 | -14% | +25 points |
| Q4 2024 | -24% | +23 points |
MIRM's operating margin was −32% last quarter, down 34 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MIRM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over MIRM on profitability, with a higher operating margin.
MIRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.6M | -114% |
| Q2 2026 | -$44.3M | -472% |
| Q1 2026 | -$229.4M | -$227.4M |
| Q4 2025 | $5.5M | +$10.6M |
| Q3 2025 | $39.5M | +938% |
| Q2 2025 | $11.9M | +$16.5M |
| Q1 2025 | -$2M | -113% |
| Q4 2024 | -$5.1M | +$11.5M |
MIRM has burned cash in most quarters: −$274M over the past year, against $44M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MIRM on cash generation, producing positive trailing cash flow while its opponent burns cash.
MIRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.2% | +2.7M shares |
| 1 year | +16% | +9.1M shares |
| 3 years | +61% | +25M shares |
| 5 years | +117% | +35.7M shares |
| Available history | +167% | +41.3M shares |
MIRM has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MIRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 6.2x | High |
MIRM's net debt is about 6.2 years of its operating earnings (EBITDA).
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
MIRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.3 | Neutral |
| Stochastic | 43.7 | Neutral |
MIRM's weekly RSI is 49 (neutral) and its Stochastic is 44 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MIRM PE vs Healthcare Sector
MIRM has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MIRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $86.4 | 8% above |
| 20 week MA | $98.1 | 4.9% below |
| 50 week MA | $95.4 | 2.2% below |
| 100 week MA | $75.2 | 24% above |
| 200 week MA | $52.8 | 77% above |
MIRM's trend is mixed: it's above three of its five weekly moving averages, and 77% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over MIRM on trend strength, trading above more of its moving averages.
MIRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.9 | $18.3 | -30% |
| 2021 | $18.3 | $15.6 | -15% |
| 2022 | $15.6 | $18.2 | +17% |
| 2023 | $18.2 | $29.5 | +62% |
| 2024 | $29.5 | $41.6 | +41% |
| 2025 | $41.6 | $79.3 | +91% |
| 2026 YTD | $79.3 | $93.3 | +18% |
MIRM has finished higher in four of the last six years, two of them by more than 50%. It's up 18% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MIRM on returns for 2026, with the stronger performance.